Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02361944
Other study ID # 131128
Secondary ID R01GM112871
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date April 5, 2016
Est. completion date January 8, 2021

Study information

Verified date January 2024
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will recruit and randomize 200 elective cardiac surgery patients to receive physiologic oxygenation (normoxia) or hyper-oxygenation (hyperoxia) during surgery to test the hypothesis that intraoperative physiologic oxygenation decreases the generation of reactive oxygen species, oxidative damage, and postoperative organ injury compared to hyper-oxygenation.


Recruitment information / eligibility

Status Completed
Enrollment 213
Est. completion date January 8, 2021
Est. primary completion date October 8, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Open-heart cardiac surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy. Exclusion Criteria: - Current acute coronary syndrome (defined as ST elevation myocardial infarction or non-ST elevation myocardial infarction (troponin leak within 72 hours of surgery or consent +/- EKG changes consistent with myocardial ischemia)). - Home supplemental oxygen use. - Preoperative supplemental oxygen requirement to maintain arterial O2 sat of 92%. - Right to left intracardiac shunt including atrial septal defect and ventricular septal defect with Cor Pulmonale. - Carotid stenosis defined as >50% stenosis. - Cardiac surgery that requires intraoperative circulatory arrest, such as aortic arch replacement. - Current use of hemo- or peritoneal dialysis. - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxygen - normoxia
Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Oxygen - hyperoxia
Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass

Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraoperative Systemic Oxidative Damage quantified by measuring F2-isoprostanes isofurans following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Primary Acute Kidney Injury quantified by change in serum creatinine concentration baseline to postoperative day 2
Secondary Vascular Reactivity / Endothelial Function (as Measured by Flow Mediated Dilation) brachial artery flow mediated dilation assessed when patient arrives in ICU after surgery. brachial artery flow mediated dilation is represented as the percent change in brachial artery diameter following 5 minutes of artery occlusion. The entire assessment takes place at ICU admission. ICU admission (immediately after arrival in ICU from operating room)
Secondary Mitochondrial Function mitochondrial function in atrial myocardium estimated by quantifying adenylate kinase at the end of surgery and oxygen intervention up to 2 days following surgery
Secondary Number of People With Arrhythmia defined as any atrial fibrillation following surgery until hospital discharge assessed using continuous telemetry, rhythm strips, and electrocardiograms from surgery to hospital discharge, average of 6 days following surgery
Secondary Myocardial Injury or Infarction plasma concentration of creatine kinase, myocardial band morning of postoperative day 1
Secondary Number of People With Stroke Defined as new deficit on neurologic exam and confirmed with radiologic evidence occurring at any point prior to hospital discharge from surgery to hospital discharge, average of 6 days following surgery
Secondary Postoperative Cognitive Dysfunction Median change scores at the Short Blessed Scale (SBT) administered one-year following surgery. The SBT is a validated rating scale, administered by the clinician, measuring the cognitive performance. Sum Total (range 0-28) with 0 indicating no cognitive impairment and 28 indicating severe cognitive impairment. up to 18 months following surgery
Secondary Respiratory Failure reintubation from surgery to hospital discharge, average of 6 days following surgery
Secondary Chronic Kidney Disease eGFR one year following surgery 12 months following surgery
Secondary Inflammation Estimated by quantifying plasma concentration of plasminogen activator inhibitor-1 (PAI-1) up to 2 days following surgery
Secondary Hemolysis plasma free hemoglobin separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Reactive Oxygen Species Production TMH electron spin probe end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Acute Brain Dysfunction (Delirium) The number of participants with acute brain dysfunction as assessed by the Confusion Assessment Method for the ICU (CAM-ICU) twice daily while patients are in the ICU or for first 3 postoperative days. from surgery to hospital discharge, average of 6 days following surgery
Secondary Oxygenation and Perfusion (Lactate) arterial lactate measured from arterial blood collected at ICU admission (immediately after arrival in ICU from operating room) ICU admission (immediately after arrival in ICU from operating room)
Secondary Acute Kidney Injury, According to KDIGO Criteria KDIGO acute kidney injury is defined as an increase in SCr = 0.3 mg/dL (= 26.5 lmol/L) within 48 hours of surgery or 1.5 to 1.9 times baseline within 7 days of surgery up to 7 days following surgery
Secondary Acute Kidney Injury Estimated by Urine Concentration of TIMP-2 IGFBP7 Urinary concentration of [TIMP2]*[IGFBP7] 6 hours after ICU admission baseline to 2 days following surgery
Secondary Acute Kidney Injury Estimated by Urine Concentration of NGAL Urinary concentration of neutrophil gelatinase-associated lipocalin (NGAL) 6 hours after ICU admission. baseline to 2 days following surgery
Secondary Reactive Oxygen Species Production CAT1H electron spin probe end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Oxygenation and Perfusion (SpO2) hemoglobin O2 saturation summarized using SpO2 data continuously measured and recorded every minute during surgery. We calculated the median SpO2 throughout surgery using all the minute to minute values. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 SpO2 measurements. We calculated and report the median of those measurements. during surgery
Secondary Oxygenation and Perfusion (PaO2) partial pressure of oxygen in arterial blood measured from blood sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention) end of surgery, defined as separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Oxygenation and Perfusion (Cerebral Oximetry) brain hemoglobin oxygenation using near-infrared spectroscopy (NIRS). The median percent changes from baseline (baseline measured at beginning of surgery when probes placed on forehead, prior to intervention) throughout surgery was calculated using cerebral oximetry measurements collected every minute throughout surgery. We calculated the difference between baseline and each measurement throughout surgery. For example, if a participant had a 5 hour (300 minutes) long surgery, the participant would have 300 cerebral oximetry measurements. We calculated and report the median of those measurements. continuously assessed throughout surgery and recorded each minute
Secondary Oxygenation and Perfusion (SvO2) mixed venous O2 saturation, measured from blood sampled from pulmonary artery sampled at end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention) end of surgery, defined as following separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Oxygenation and Perfusion (Cardiac Index) cardiac output (normalized to body surface area, i.e., cardiac index) end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Vascular Reactivity / Endothelial Function (Peripheral Artery Tonometry) reactive hyperemia index measured at ICU admission (immediately after arrival in ICU from operating room). The reactive hyperemia index is a number generated by an endopat machine performing peripheral artery tonometry. The index ranges from approximately 1-3, where higher values indicate better vascular reactivity and endothelial function. ICU admission (immediately after arrival in ICU from operating room)
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, EC50) Effective concentration for 50% dilation acetylcholine dose response, tension wire myography from arterioles dissected from epicardial fat tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Dependent Vasodilation, Emax) Maximum percentage of arteriole dilation after increasing doses of acetylcholine measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention. tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, EC50) Effective concentration for 50% dilation sodium nitroprusside dose response, tension wire myography from arterioles dissected from epicardial fat tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, Endothelial Independent Vasodilation, Emax) Maximum percentage of arteriole dilation after increasing doses of sodium nitroprusside measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention. tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, EC50) Effective concentration for 50% dilation cinaciguat dose response, tension wire myography from arterioles dissected from epicardial fat tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (Tension Wire Myography, sGC Activation Vasodilation, Emax) Maximum percentage of arteriole dilation after increasing doses of cinaciguat measured using tension wire myography of arterioles dissected from epicardial fat. The fat sample was collected during surgery when heart is exposed approximately 2 hours into intervention. tissue collected during surgery when heart is exposed approximately 2 hours into intervention
Secondary Vascular Reactivity / Endothelial Function (PAI-1) Plasminogen activator inhibitor 1 end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
Secondary Vascular Reactivity / Endothelial Function (E-selectin) E-selectin end of surgery, defined as immediately after separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3